recurrent plasma cell myeloma
Showing 26 - 50 of 70
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Recruiting
- Plasma Cell Myeloma
- +2 more
- Belantamab Mafodotin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 10, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Recurrent Plasma Cell Myeloma Trial in Rochester (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +3 more
-
Rochester, MinnesotaMayo Clinic in Rochester
May 19, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,
Terminated
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 6, 2022
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,
Active, not recruiting
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- ixazomib citrate
- +2 more
-
Scottsdale, Arizona
- +4 more
Mar 28, 2022
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Pembrolizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 23, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory
Suspended
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +5 more
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta
Active, not recruiting
- ISS Stage I Plasma Cell Myeloma
- +4 more
- Pembrolizumab
- Radiation Therapy
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Mar 2, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
-
Calgary, Alberta, Canada
- +4 more
Feb 10, 2022
Hematopoietic and Lymphoid Cell Tumor, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome Trial in Houston
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +13 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Houston, TexasM D Anderson Cancer Center
Feb 8, 2022
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Dexamethasone, Leflunomide, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 10, 2022
Recurrent Plasma Cell Myeloma Trial in Houston (Daratumumab)
Recruiting
- Recurrent Plasma Cell Myeloma
- Daratumumab
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2021
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma Trial in Richmond (mycophenolate mofetil, Sargramostim, Filgrastim)
Active, not recruiting
- Hodgkin's Lymphoma
- +17 more
- mycophenolate mofetil
- +2 more
-
Richmond, VirginiaVirginia Commonwealth University/Massey Cancer Center
Dec 21, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Laboratory Biomarker Analysis, Lenalidomide,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic
Dec 1, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (CS1-CAR T Therapy, Cyclophosphamide, Fludarabine)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- CS1-CAR T Therapy
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 15, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Laboratory Biomarker Analysis, Leflunomide,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 4, 2021
Frequency of Cachexia in Ambulatory Cancer Patients and
Recruiting
- Advanced Malignant Solid Neoplasm
- +6 more
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Oct 1, 2021
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,
Terminated
- Multiple Myeloma-Light Chain Only
- +2 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2021
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Tumor, Recurrent Acute Lymphoblastic Leukemia Trial
Completed
- Allogeneic Hematopoietic Stem Cell Transplant Recipient
- +10 more
- Ipilimumab
- +2 more
-
Duarte, California
- +12 more
Jun 23, 2021
Recurrent Plasma Cell Myeloma Trial in Columbus (Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis)
Completed
- Recurrent Plasma Cell Myeloma
- Dexamethasone
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Jun 10, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bendamustine Hydrochloride
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 7, 2021
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma Trial in Durham, Portland (procedure, drug, other)
Completed
- Plasma Cell Leukemia
- Recurrent Plasma Cell Myeloma
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Durham, North Carolina
- +1 more
Nov 19, 2020